PACS

PACS Group, Inc. (PACS) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2026. PACS Group, Inc. is a leading post-acute healthcare company operating 324 skilled nursing, assisted living, and independent living facilities across 17 states. As of the reporting date, the company operated 32,790 skilled nursing beds and 2,841 assisted living beds. The company's strategy focuses on acquiring underperforming facilities and transforming them into higher-acuity, short-term transitional care facilities.

Key Financial Metrics

Note: Total Debt includes $246,842 in HUD-insured mortgages and $3,127 in other non-HUD loans, less current maturities and deferred financing fees.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9.1% year-over-year for the quarter and 10.1% for the six-month period. Skilled nursing services revenue grew 7.7% (quarter) and 8.8% (six months), driven by a 3.9% increase in patient days and improved occupancy rates.
• Profitability: Net income attributable to PACS increased 49.8% for the quarter and 97.9% for the six months ended June 30, 2026, compared to the prior year periods.
• Operating Expenses: Cost of services increased 6.7% (quarter) and 5.8% (six months), primarily due to higher salaries and wages ($25.5M and $65.0M increases, respectively) and increased liability insurance costs. General and administrative expenses rose 13.9% due to operational growth and higher stock-based compensation, partially offset by a decrease in legal fees related to prior investigations.
• Occupancy and Mix: Same-store occupancy improved to 90.6% (quarter) and 90.8% (six months). Skilled mix by revenue increased to 50.0% (quarter) and 50.3% (six months).
• Capital Allocation: The company invested $190.8 million in facility acquisitions and $48.4 million in property and equipment during the first six months of 2026. The company repaid $100 million on its line of credit, leaving a $0 balance as of June 30, 2026.

Guidance, Outlook, Risks, and Contingencies

Outlook and Capital Resources: Management believes current cash balances and operating cash flows are sufficient to cover operating needs for at least the next 12 months. A $250 million share repurchase program was authorized in May 2026; no shares were repurchased as of June 30, 2026. The company continues to pursue opportunistic acquisitions, adding 20 facilities (2,312 beds) subsequent to the reporting period.

Material Weaknesses in Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses in the control environment and revenue recognition processes. These weaknesses led to the restatement of prior financial statements. Remediation efforts are ongoing, including the hiring of a Chief Compliance Officer and enhanced revenue controls.

Legal and Regulatory Risks:

• DOJ Investigations: The company is cooperating with multiple ongoing Department of Justice investigations regarding potential False Claims Act violations, including allegations related to patient referrals, billing practices under the Patient-Driven Payment Model (PDPM), and the use of the 1135 COVID-19 waiver.
• SEC Investigation: The SEC is investigating the company's accounting, financial reporting, and internal controls.
• Securities Litigation: A consolidated securities class action (Manchin v. PACS Group, Inc.) and shareholder derivative actions allege a scheme to inflate revenue and profitability. The company has moved to dismiss these complaints, which are fully briefed as of June 2026.

Credit Facility Status: The company has a $600 million revolving credit facility. While it was in compliance with covenants as of June 30, 2026, it has recently entered into multiple amendments and forbearance agreements regarding technical events of default related to financial statement delivery and representations. A liquidity requirement to maintain $100 million in unrestricted cash was in place until the delivery of Q2 2026 financial statements.

Key Facts for Investor Verification

• Internal Control Remediation: Verify the progress of remediation plans for material weaknesses in revenue recognition and the control environment, and assess the timeline for declaring controls effective.
• Regulatory Outcomes: Monitor the status of DOJ and SEC investigations, as well as the securities class action litigation, for potential fines, penalties, or restatements.
• Debt Covenants: Confirm continued compliance with the Amended and Restated Credit Facility, particularly regarding the liquidity requirement and any future forbearance agreements.
• Acquisition Integration: Assess the financial performance and integration of the 20 facilities acquired subsequent to June 30, 2026, and the 4 facilities added during the quarter.
• Self-Insurance Liabilities: Review the adequacy of the $394.9 million self-insurance liability reserve, which includes significant unasserted claims.